Fast-expanding Shanghai Pharma breaks ground on $1.8B biotech park focused on next-gen R&D, antibody production

One of China’s biggest biopharma companies is hitting the ground running in 2021.

Shanghai Pharmaceuticals broke ground Monday on a $1.8 billion, 3.2 million-square-foot industrial park dedicated to R&D work in the bustling field of cell and gene therapies as well as manufacturing therapeutic antibodies, the firm said.